The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

• Published in: Journal of experimental & clinical cancer research Vol. 39; no. 1; pp. 284 - 17
• Main Authors: Jia, Xiao-Hui, Geng, Lu-Ying, Jiang, Pan-Pan, Xu, Hong, Nan, Ke-Jun, Yao, Yu, Jiang, Li-Li, Sun, Hong, Qin, Tian-Jie, Guo, Hui
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.12.2020; BioMed Central; BMC
• Subjects: Antigens; Autoantibodies; Autoimmune diseases; Autoimmunity; B cells; Biological markers; Biomarkers; Cancer therapies; Complications and side effects; Cytokines; Dermatitis; Gastrointestinal system; Hypotheses; Immune checkpoint inhibitors; Immunotherapy; Inflammation; Inflammatory bowel disease; Ipilimumab; Kidney cancer; Lymphocytes; Medical prognosis; Melanoma; Patients; Pneumonia; Proteins; Review; Skin cancer; Tumors

The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle to the prospect of ICI treatment. IrAEs are a...